{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:04:32Z","timestamp":1782601472279,"version":"3.54.5"},"reference-count":41,"publisher":"BMJ","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pathol"],"published-print":{"date-parts":[[2008,8]]},"abstract":"<jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>The mammalian target of rapamycin (mTOR), an important regulator of protein translation and cell proliferation, is activated in various malignancies. In a randomised controlled trial of advanced renal cell carcinoma patients, targeted therapy to mTOR by means of rapamycin analogues has been shown to significantly improve survival. An in vitro study has revealed that mTOR is activated in oesophageal squamous cell carcinoma (OSCC) cell lines and that mTOR expression is inhibited by rapamycin. The objectives of this histological study were to determine the proportion of OSCC tissues with activated mTOR (p-mTOR) expression, thereby assessing the percentage of patients with OSCC that would possibly benefit from neoadjuvant rapamycin therapy, and to identify the clinicopathological features of these potentially rapamycin-sensitive tumours.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The expression of p-mTOR (Ser2448) was immunohistochemically assessed in a validated tissue microarray comprising triplicate tissue biopsy cores of 108 formalin-fixed, paraffin-embedded OSCCs. Staining results were correlated with clinicopathological data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Normal oesophageal epithelium was negative for p-mTOR. Activated mTOR expression was located in the cytoplasm of oesophageal tumour cells. 26 (25%) of 105 assessable OSCCs showed tumour cells with positive staining for activated mTOR. Activated mTOR expression was associated with a lesser degree of differentiation only (p\u200a=\u200a0.024). No correlation was detected between p-mTOR and the proliferation marker Ki-67.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Activated mTOR can be detected in one-quarter of OSCCs. Since this subset of patients may potentially benefit from mTOR inhibiting therapy, a phase II clinical trial of neoadjuvant mTOR-inhibiting therapy in patients with OSCC may be considered.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jcp.2008.055772","type":"journal-article","created":{"date-parts":[[2008,5,12]],"date-time":"2008-05-12T20:34:21Z","timestamp":1210624461000},"page":"909-913","source":"Crossref","is-referenced-by-count":32,"title":["mTOR in squamous cell carcinoma of the oesophagus: a potential target for molecular therapy?"],"prefix":"10.1136","volume":"61","author":[{"given":"J","family":"Boone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F J W Ten","family":"Kate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G J A","family":"Offerhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P J","family":"van Diest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I H M Borel","family":"Rinkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"van Hillegersberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2008,5,12]]},"reference":[{"key":"2025112108163782000_61.8.909.1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.2308"},{"key":"2025112108163782000_61.8.909.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70172-9"},{"key":"2025112108163782000_61.8.909.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2006.03.012"},{"key":"2025112108163782000_61.8.909.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022343"},{"key":"2025112108163782000_61.8.909.5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70039-6"},{"key":"2025112108163782000_61.8.909.6","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.10-8-590"},{"key":"2025112108163782000_61.8.909.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2004.09.009"},{"key":"2025112108163782000_61.8.909.8","first-page":"895","article-title":"Mammalian target of rapamycin: master regulator of cell growth in the nervous system.","volume":"22","author":"Sandsmark","year":"2007","journal-title":"Histol Histopathol"},{"key":"2025112108163782000_61.8.909.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcdb.2004.11.005"},{"key":"2025112108163782000_61.8.909.10","doi-asserted-by":"publisher","DOI":"10.1002\/pros.20410"},{"key":"2025112108163782000_61.8.909.11","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800525"},{"key":"2025112108163782000_61.8.909.12","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22677"},{"key":"2025112108163782000_61.8.909.13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0112"},{"key":"2025112108163782000_61.8.909.14","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209886"},{"key":"2025112108163782000_61.8.909.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066838"},{"key":"2025112108163782000_61.8.909.16","doi-asserted-by":"publisher","DOI":"10.1002\/cbf.1332"},{"key":"2025112108163782000_61.8.909.17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0483"},{"key":"2025112108163782000_61.8.909.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2007.01.026"},{"key":"2025112108163782000_61.8.909.19","doi-asserted-by":"publisher","DOI":"10.1038\/nm0798-844"},{"key":"2025112108163782000_61.8.909.20","doi-asserted-by":"publisher","DOI":"10.1017\/S1462399403006549"},{"key":"2025112108163782000_61.8.909.21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.325.7365.648"},{"key":"2025112108163782000_61.8.909.22","unstructured":"Gabbert HE . Squamous cell carcinoma of the esophagus. In: Hamilton S R Aaltonen L A , eds. WHO classification of tumours \u2013 pathology and genetics of tumours of the digestive system. Lyon, France: IARC Press, 2000:10\u20136."},{"key":"2025112108163782000_61.8.909.23","unstructured":"Wittekind C Greene FL Hutter RVP . TNM atlas. Illustrated guide to the TNM\/pTNM classification of malignant tumors. Berlin: Springer-Verlag, 2004."},{"key":"2025112108163782000_61.8.909.24","doi-asserted-by":"crossref","unstructured":"Boone J van Hillegersberg R van Diest PJ . Validation of tissue microarray technology in squamous cell carcinoma of the esophagus. Virchows Archiv. Published Online First: 8 April 2008. doi:10.1007\/s00428-008-0602-0.","DOI":"10.1007\/s00428-008-0602-0"},{"key":"2025112108163782000_61.8.909.25","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602862"},{"key":"2025112108163782000_61.8.909.26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0738"},{"key":"2025112108163782000_61.8.909.27","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3748\/wjg.v8.i2.200","article-title":"The abnormal expression of retinoic acid receptor-beta, p53 and Ki67 protein in normal, premalignant and malignant esophageal tissues.","volume":"8","author":"Xu","year":"2002","journal-title":"World J Gastroenterol"},{"key":"2025112108163782000_61.8.909.28","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2007.64"},{"key":"2025112108163782000_61.8.909.29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.66.130"},{"key":"2025112108163782000_61.8.909.30","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800834"},{"key":"2025112108163782000_61.8.909.31","first-page":"283","article-title":"Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas.","volume":"36","author":"Lin","year":"2006","journal-title":"Ann Clin Lab Sci"},{"key":"2025112108163782000_61.8.909.32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1041"},{"key":"2025112108163782000_61.8.909.33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0941"},{"key":"2025112108163782000_61.8.909.34","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22442"},{"key":"2025112108163782000_61.8.909.35","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000252780.42104.95"},{"key":"2025112108163782000_61.8.909.36","doi-asserted-by":"crossref","unstructured":"Noh WC Kim YH Kim MS . Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables. Breast Cancer Res Treat. Published Online First: 6 September 2007. doi:10.1007\/s10549-007-9746-x.","DOI":"10.1007\/s10549-007-9746-x"},{"key":"2025112108163782000_61.8.909.37","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200606000-00001"},{"key":"2025112108163782000_61.8.909.38","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-437X(01)00265-9"},{"key":"2025112108163782000_61.8.909.39","doi-asserted-by":"publisher","DOI":"10.1016\/S0955-0674(98)80123-3"},{"key":"2025112108163782000_61.8.909.40","doi-asserted-by":"publisher","DOI":"10.1023\/A:1010615822317"},{"key":"2025112108163782000_61.8.909.41","first-page":"1453","article-title":"Alterations of p53, cyclin D1 and pRB expression in the carcinogenesis of esophageal squamous cell carcinoma.","volume":"14","author":"Kawakubo","year":"2005","journal-title":"Oncol Rep"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jcp.2008.055772","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T16:16:43Z","timestamp":1763741803000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jcp.2008.055772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,12]]},"references-count":41,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2008,7,28]]},"published-print":{"date-parts":[[2008,8]]}},"alternative-id":["10.1136\/jcp.2008.055772"],"URL":"https:\/\/doi.org\/10.1136\/jcp.2008.055772","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,12]]}}}